• Our venture partners
  
• Corporate accomplishments
  
• Events
  
• FAQs
  

About NeoVista, Inc.

Corporate accomplishments

NeoVista, Inc., has made rapid progress toward its goal of commercialization of its new treatment technology for wet AMD. Some of the highlights of our corporate achievements are listed here:

• CE mark received: this permits NeoVista to market its epimacular beta radiation therapy outside the United States; we are targeting 17 markets for product introduction within the next 24 months.
• Quality-adjusted life-year (QALY) analysis completed: QALY provides a way of measuring disease burden, including both the quality and the quantity of life lived, as a means of quantifying the benefit of a medical intervention. In this study the NeoVista therapy was shown to be more beneficial than treatment with Lucentis.
• Ongoing clinical studies: The safety and efficacy of the investigational NeoVista treatment is being studied in several controlled clinical trials, including a pivotal Phase III study; see the NeoVista clinical studies section of this site for more information.
• Category III code assigned with HOPD/ASC reimbursement in place: this code allows separate listing of the placement of the intraocular radiation source applicator and will help us track utilization of the NeoVista investigational therapy at all study sites.
• Two peer-reviewed papers submitted:
  • Avila MP, Farah ME, Santos A, Kapran Z, Duprat JP, Woodward BW, Nau J. Twelve-month safety and visual acuity results from a feasibility study of intraocular epimacular radiation therapy for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration.
  • Brown MM, Brown GC, Brown HC, Irwin B, Roth Z. The comparative effectiveness and cost-effectiveness of intraocular 90Sr brachytherapy and intravitreal VEGF inhibitor therapy for the treatment of neovascular macular degeneration.
• One peer reviewed paper accepted for publication:
  • Avila MP, Farah ME, Santos A, Duprat JP, Woodward BW, Nau J. Twelve-month short-term safety and visual acuity results from a multicenter prospective study of epimacular strontium-90 brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration.
• OUS introduction of first commercial product: the VIDION™ Anti-Neovascular (ANV) Therapy System will be available for use outside the United States in early 2009.

Click here to learn about the clinical accomplishments that go hand-in-hand with our corporate advances.